Company & Sponsor Intelligence
Zogenix, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting1
Completed2
Countries1
Therapeutic footprint
epilepsymigraine_headacheschizophrenia
Indexed studies
NCT02411526Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
schizophrenia · United StatesPHASE1
schizophrenia · United StatesPHASE1
NCT05064878A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT03780127ZX008 Expanded Access Protocol
epilepsy · APPROVED_FOR_MARKETING
epilepsy · APPROVED_FOR_MARKETING
NCT01016834Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine
migraine_headache · United StatesPHASE4
migraine_headache · United StatesPHASE4
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →